Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for ADC Therapeutics (ADCT) over the last 7 years, with Dec 2024 value amounting to $97.1 million.

  • ADC Therapeutics' Cash from Financing Activities rose 99.89% to -$1,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $73.9 million, marking a year-over-year increase of 8335.79%. This contributed to the annual value of $97.1 million for FY2024, which is 31.38% up from last year.
  • As of FY2024, ADC Therapeutics' Cash from Financing Activities stood at $97.1 million, which was up 31.38% from $73.9 million recorded in FY2023.
  • ADC Therapeutics' Cash from Financing Activities' 5-year high stood at $495.0 million during FY2020, with a 5-year trough of -$897,000 in FY2022.
  • In the last 3 years, ADC Therapeutics' Cash from Financing Activities had a median value of $73.9 million in 2023 and averaged $56.7 million.
  • As far as peak fluctuations go, ADC Therapeutics' Cash from Financing Activities slumped by 100.34% in 2022, and later skyrocketed by 8,335.79% in 2023.
  • Yearly analysis of 5 years shows ADC Therapeutics' Cash from Financing Activities stood at $495.0 million in 2020, then crashed by 45.98% to $267.4 million in 2021, then crashed by 100.34% to -$897,000 in 2022, then spiked by 8,335.79% to $73.9 million in 2023, then skyrocketed by 31.38% to $97.1 million in 2024.